FIELD: pharmacology.
SUBSTANCE: invention relates to the field of medicine and pharmacy, namely to the application of the compound of formula I:
(I),
or its deuterated compound, or a pharmacologically acceptable salt for the preparation of a drug for the treatment of cerebral microangiopathy in a patient, wherein cerebral microangiopathy is a cerebral microbleed, and R1 is an H, alkyl, or terminal alkenyl containing 1 to 5 carbon atoms, or -CH(CH3)(CH2)3CH(CH3)2.
EFFECT: invention provides the use of compounds that significantly improve the excretion of extravascular hemoglobin and can thus be used for the treatment of cerebral microangiopathy.
13 cl, 7 dwg, 3 ex
| Title | Year | Author | Number |
|---|---|---|---|
| APPLICATION OF COMPOUNDS FOR PRODUCING MEDICINAL PRODUCT FOR TREATING HEMORRHAGIC STROKE | 2018 |
|
RU2752090C1 |
| NEUROPROTECTIVE AGENTS AND THEIR APPLICATION | 2015 |
|
RU2672264C2 |
| USE OF BISPHOSPHONATES AS HIV/AIDS ADJUNCTIVE TREATMENT | 2015 |
|
RU2671973C2 |
| CELLULAR SYSTEM FOR TARGETED DELIVERY OF A PHARMACEUTICALLY ACTIVE SUBSTANCE OR LABEL | 2016 |
|
RU2771323C2 |
| SPECIFIC HEXOKINASE-2 INHIBITORS FOR USE IN ACUTE CENTRAL NERVOUS SYSTEM DAMAGE | 2018 |
|
RU2736499C1 |
| HYBRID PROTEIN IGF-1-LONG FOR TREATING STROKE, NUCLEIC ACID, VECTOR, CELL, PHARMACEUTICAL COMPOSITION, METHOD OF TREATMENT | 2018 |
|
RU2711111C1 |
| CDP-CHOLINE - PROPHYLACTIC AGENT FOR TREATMENT OF CEREBRAL ISCHEMIA AND METHOD FOR TREATMENT WITH ITS USING | 2001 |
|
RU2255741C2 |
| METHOD OF REDUCING AMYLOID DEPOSITION, AMYLOID NEUROTOXICITY AND MICROGLYOSIS BY (-)-ENANTIOMER NILVADIPINE | 2008 |
|
RU2490014C2 |
| MODULATION OF AQUAPORINS WITH RELAXIN | 2011 |
|
RU2564900C2 |
| AGENT ENHANCING EFFECT OF REHABILITATION AFTER NERVE DAMAGE WHICH CONTAINS SIMPLE ALKYL ETHER DERIVATIVE OR SALT THEREOF | 2015 |
|
RU2680247C2 |
